Resilience as the cornerstone of medical device manufacturing

By Marco Fernandez, Strategic Account Manager at East West Manufacturing

Medical device manufacturers are rethinking traditional outsourcing frameworks, moving away from low-cost prioritisation and towards resilience-led supply chain strategies. In 2026, cost alone is no longer a strong enough foundation.

For years, cost efficiency defined global manufacturing models, built around lean inventories, concentrated production, and streamlined supplier networks. But tariff volatility, geopolitical uncertainty, and ongoing supply chain disruption have made cost increasingly unpredictable, exposing the limits of systems designed purely for efficiency.

As a result, these pressures are being felt across industries, especially highly regulated sectors like medical device manufacturing. Supplier changes often require validation, documentation, and regulatory approval, meaning manufacturers cannot always respond quickly when disruption occurs. For UK and European OEMs operating under frameworks such as EU MDR and UKCA, these constraints are particularly significant, stifling flexibility at a time when agility is increasingly critical.

In a healthcare setting, the consequences of a break in supply are amplified. Hospitals, clinics, and other medical facilities all rely on consistent access to products, with significant knock-on effects from any shortages. This dependency must inform and shape how manufacturers approach risk; cost should remain a central consideration, but planning for resilience is becoming equally important.

In response, a more balanced approach is beginning to emerge, where resilience is applied selectively. This includes multi-location strategies, dual-sourcing for critical components, and greater visibility across the supply chain, while maintaining cost discipline in lower-risk areas.

Where cost-led strategies begin to break down

Cost-led models still offer clear benefits. Lower-cost locations can support margins, while lean inventory models help reduce capital tied up in stock, and these remain central to a supply chain strategy.

Recent global events have exposed where this approach can fall short. Systems designed primarily for efficiency are often less able to absorb sudden change, whether driven by tariffs, geopolitical tension, or shifting demand. For medical device manufacturers, this is compounded by regulatory constraints that add a further layer of complexity, reducing the pace at which changes can be made.

In any highly regulated environment, resilience goes beyond sourcing decisions. Adjusting supplier networks requires formal validation and documentation, overseen by bodies such as the Medicines and Healthcare products Regulatory Agency (MHRA), which makes a reactive response more challenging.

This is driving a fundamental shift in how supply chains are being designed. Rather than treating resilience as a response to disruption, manufacturers are beginning to embed it from the outset to maintain continuity.

Resilient manufacturing

In practice, this means a more targeted, selective approach. Not every component or supplier presents the same level of risk, so manufacturers are concentrating on the areas where disruption would have the most significant impact. Typically, this would include critical parts, longer-lead time materials, and areas where regulatory requirements limit flexibility.

Practical measures include introducing secondary suppliers, distributing production across multiple sites, and holding selected inventory where it adds the most value. Increasing visibility across the supply chain is also key, enabling potential issues to be identified earlier and managed accordingly.

These steps admittedly can increase complexity and, in some cases, incur higher costs. However, they provide a level of flexibility that strictly cost-focused models cannot, and in regulated environments where rapid change is not always possible, flexibility is crucial. Resilience is not about eliminating risk, but about planning for it in order to reduce its impact.

Why location is becoming a strategic priority

As supply chains evolve, location is also becoming a more strategic consideration. Manufacturers are increasingly selecting sites based on how well regions support both efficiency and resilience, rather than cost alone.

Costa Rica is one example of how this approach is being implemented. Over the past two decades, it has developed into a strong medtech manufacturing base, supported by a skilled workforce, multiple universities, established infrastructure, Free Trade Zones, and alignment with global regulatory standards.

In terms of logistics, Costa Rica offers a compelling balance. Proximity to the United States enables coordination and responsiveness, whilst access to both US and European markets strengthens its position in global supply networks. For UK and European manufacturers operating under EU MDR and UKCA frameworks, locations such as Costa Rica provide stability, competitive costs, regulatory alignment, and access to international markets.

Whilst it is not the lowest-cost option, and it is not designed for very high-volume production, its value is in its balance — supporting operational efficiency whilst enabling more effective risk management.

The path to success

As global supply chains continue to shift and evolve, resilience is becoming a baseline requirement rather than a differentiator. Cost discipline will remain important for medical device manufacturers, but it is no longer the sole consideration.

Looking ahead, the best strategies will prioritise targeted investment that strengthens continuity while maintaining cost efficiency. In addition, they will turn towards locations that combine regulatory alignment, skilled talent pools, and access to international markets.

Ultimately, in medical device manufacturing, success should now be defined by the ability to deliver consistently, even if the environment and conditions are in flux.

This article originally appeared in the May/June 2026 edition of IN Electronics. Read the full issue here.